RVMD (Revolution Medicines, Inc.) Stock Financials & Earnings | Market Cap Arena

RVMD (Revolution Medicines, Inc.) Stock Financials & Earnings | Market Cap Arena

RVMDRevolution Medicines, Inc.

Mkt Cap$20B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$1.1B

EPS (TTM)-$5.95

Free Cash Flow (TTM)-$914M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$7M	$7M	-$75M
Q2 23	$4M	$4M	-$109M
Q3 23	$0	$0	-$123M
Q4 23	$742K	$742K	-$180M
Q1 24	$0	$0	-$141M
Q2 24	$0	$0	-$157M
Q3 24	$0	$0	-$176M
Q4 24	$0	$0	-$216M
Q1 25	$0	$0	-$241M
Q2 25	$0	$0	-$265M
Q3 25	$0	$0	-$315M
Q4 25	$0	-$5M	-$362M

Valuation

Quarter	P/S	P/E
Q1 23	571.1x	—
Q2 23	673.5x	—
Q3 23	759.8x	—
Q4 23	1717.1x	—
Q1 24	4354.7x	—
Q2 24	26797.4x	—
Q3 24	26797.4x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$62M	-$64M
Q2 23	-$67M	-$68M
Q3 23	-$100M	-$103M
Q4 23	-$121M	-$123M
Q1 24	-$161M	-$164M
Q2 24	-$128M	-$131M
Q3 24	-$130M	-$134M
Q4 24	-$138M	-$140M
Q1 25	-$194M	-$198M
Q2 25	-$222M	-$229M
Q3 25	-$207M	-$211M
Q4 25	-$274M	-$276M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$1M
Q3 23	$3M
Q4 23	$2M
Q1 24	$3M
Q2 24	$2M
Q3 24	$4M
Q4 24	$1M
Q1 25	$3M
Q2 25	$7M
Q3 25	$3M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-7.4%	+25.4%
Q2 23	-58.1%	+58.2%
Q3 23	-100.0%	+54.3%
Q4 23	-95.2%	+134.6%
Q1 24	-100.0%	+71.4%
Q2 24	-100.0%	+39.1%
Q3 24	—	+42.6%
Q4 24	-100.0%	+19.7%
Q1 25	—	+70.9%
Q2 25	—	+69.0%
Q3 25	—	+79.4%
Q4 25	—	+67.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$10M	138.3%
Q2 23	$13M	339.4%
Q3 23	$14M	—
Q4 23	$25M	3426.8%
Q1 24	$16M	—
Q2 24	$20M	—
Q3 24	$21M	—
Q4 24	$22M	—
Q1 25	$25M	—
Q2 25	$29M	—
Q3 25	$31M	—
Q4 25	$34M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$69M	$13M
Q2 23	$98M	$15M
Q3 23	$108M	$16M
Q4 23	$148M	$32M
Q1 24	$118M	$23M
Q2 24	$135M	$22M
Q3 24	$152M	$24M
Q4 24	$188M	$28M
Q1 25	$206M	$35M
Q2 25	$224M	$41M
Q3 25	$263M	$53M
Q4 25	$293M	$64M

Revenue Segments

Quarter	Collaboration Revenue Member
Q1 23	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$427M	$483M	$910M
Q2 23	$380M	$529M	$909M
Q3 23	$358M	$455M	$813M
Q4 23	$696M	$1.2B	$1.9B
Q1 24	$288M	$1.4B	$1.7B
Q2 24	$276M	$1.3B	$1.6B
Q3 24	$201M	$1.3B	$1.5B
Q4 24	$543M	$1.7B	$2.3B
Q1 25	$334M	$1.8B	$2.1B
Q2 25	$402M	$1.7B	$2.1B
Q3 25	$217M	$1.7B	$1.9B
Q4 25	$384M	$1.6B	$2.0B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	95M	+6.4%
Q2 23	107M	+12.7%
Q3 23	109M	+2.2%
Q4 23	141M	+29.3%
Q1 24	165M	+16.7%
Q2 24	165M	+0.3%
Q3 24	167M	+1.0%
Q4 24	168M	+0.5%
Q1 25	188M	+12.2%
Q2 25	188M	-0.0%
Q3 25	189M	+0.6%
Q4 25	190M	+0.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	$527K	95
FY 20	$344K	125
FY 21	$156K	188
FY 22	$144K	246
FY 23	$31K	378
FY 24	$0	534
FY 25	$0	200K